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Introduction
Nonsense-mediated mRNA decay (NMD) is a quality-control 
process found in all eukaryotic organisms studied to date 
(Maquat, 2004a; Conti and Izaurralde, 2005). One role of this pro-
cess is to degrade mRNA harboring a premature termination 
codon (PTC) to prevent the synthesis of truncated proteins that 
could be nonfunctional or whose function may be deleterious to 
cells. The NMD pathway has been shown to be involved in the 
regulation of gene expression in yeast, Drosophila, and mam-
mals (Sureau et al., 2001; He et al., 2003; Mendell et al., 2004; 
Wollerton et al., 2004; Rehwinkel et al., 2005).
In mammalian cells, NMD takes place after pre-mRNA 
splicing and in most cases is mediated by a protein complex de-
posited 20–24 nucleotides upstream of exon–exon junctions 
(Maquat, 2004b; Conti and Izaurralde, 2005; Lejeune and 
Maquat, 2005). This protein complex called the exon junction 
complex (EJC) is thought to recruit the evolutionarily conserved 
UPF proteins that play an essential but still not fully character-
ized role in NMD. During what is referred to as the “pioneer 
round of translation” (Ishigaki et al., 2001), PTCs are recognized 
and the targeted mRNAs are degraded by both 5′–3′ decay 
involving decapping and 5′–3′ exoribonucleases such as hXRN1 
and hXRN2/hRAT1, and by 3′–5′ decay involving deadenyl-
ation and the exosome (Chen and Shyu, 2003; Lejeune et al., 
2003; Couttet and Grange, 2004).
NMD implicates the participation of hUPF proteins such 
as hUPF1, hUPF2, hUPF3 (also named hUPF3a), and hUPF3X 
(also called hUPF3b). The function of these hUPF proteins is 
still unclear. However, it has been proposed that they are se-
quentially recruited by the EJC: hUPF3/3X fi  rst, followed by 
hUPF2, and fi  nally hUPF1 in mammalian cells (Lykke-Andersen 
et al., 2001; Kim et al., 2005). Interestingly, the function of 
hUPF2 has been demonstrated to be dispensable in some NMD 
cases, suggesting the existence of different pathways to elicit 
NMD (Gehring et al., 2005).
UPF1 is a phosphoprotein that undergoes phosphoryl-
ation/dephosphorylation cycles during NMD (Page et al., 1999; 
Pal et al., 2001; Ohnishi et al., 2003). UPF1 has been shown to 
interact with release factors in yeast (Czaplinski et al., 1998) and 
mammals (Kashima et al., 2006), and could link the EJC and 
translation termination complex. A direct interaction between 
hUPF1 and the cap-binding protein CBP80 has also recently 
been demonstrated in mammalian cells (Hosoda et al., 2005), 
indicating that hUPF1 establishes a complex interaction net-
work either before or during the pioneer round of translation. 
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n mammals, nonsense-mediated mRNA decay (NMD) 
is a quality-control mechanism that degrades mRNA 
harboring a premature termination codon to prevent 
the synthesis of truncated proteins. To gain insight into 
the NMD mechanism, we identiﬁ  ed NMD inhibitor 1 
(NMDI 1) as a small molecule inhibitor of the NMD path-
way. We characterized the mode of action of this com-
pound and demonstrated that it acts upstream of hUPF1. 
NMDI 1 induced the loss of interactions between hSMG5 
and hUPF1 and the stabilization of hyperphosphorylated 
isoforms of hUPF1. Incubation of cells with NMDI 1 allowed 
us to demonstrate that NMD factors and mRNAs subject 
to NMD transit through processing bodies (P-bodies), 
as is the case in yeast. The results suggest a model in 
which mRNA and NMD factors are sequentially recruited 
to P-bodies.
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Phosphorylation of hUPF1 has been shown to be performed by 
hSMG1, a phosphoinositide 3-kinase–related kinase (Page et al., 
1999; Pal et al., 2001; Yamashita et al., 2001), and requires the 
presence of hUPF2 and hUPF3 (Kashima et al., 2006). In con-
trast, dephosphorylation of hUPF1 requires the presence of a 
multiprotein complex composed of hSMG5, hSMG6, hSMG7, 
and protein phosphatase 2A (Chiu et al., 2003; Ohnishi et al., 
2003). For the most part, hSMG5 and hSMG7 proteins are dis-
tributed evenly throughout the cytoplasm, but a fraction is also pre-
sent in processing bodies (P-bodies; Unterholzner and Izaurralde, 
2004). hSMG6 is a cytoplasmic protein that concentrates in 
cytoplasmic foci distinct from P-bodies and whose nature is 
still unclear (Unterholzner and Izaurralde, 2004).
P-bodies have been described in lower and higher eukary-
otic cells (Ingelfi  nger et al., 2002; van Dijk et al., 2002; Sheth 
and Parker, 2003; Cougot et al., 2004). In mammals, these cyto-
plasmic structures contain many factors involved in mRNA de-
cay, including components of the decapping machinery such as 
decapping protein 1a (DCP1a; Ingelfi  nger et al., 2002), DCP2 
(Ingelfi  nger et al., 2002; van Dijk et al., 2002), GE1 (also called 
Hedls; Fenger-Gron et al., 2005; Yu et al., 2005), p54/RCK 
(Cougot et al., 2004), the deadenylase CCR4 (Cougot et al., 
2004), XRN1 (Bashkirov et al., 1997), the LSM1-7 complex 
  involved in different aspects of RNA processing (Cougot et al., 
2004; Ingelfi  nger et al., 2002), and the hUPF1, hSMG5, and 
hSMG7 components of the NMD machinery (Unterholzner and 
Izaurralde, 2004; Fukuhara et al., 2005). The function of P-bodies 
is still unclear but they may serve as a storage compartment for 
both untranslated RNAs and proteins involved in RNA decay 
(Brengues et al., 2005; Pillai et al., 2005; Teixeira et al., 2005; 
Franks and Lykke-Andersen, 2007), and/or as a site for RNA 
decay (Cougot et al., 2004; Sheth and Parker, 2006).
In a recent work, we showed that hydrophobic tetra-
cyclic indole derivatives block the function of specifi  c splicing 
factors (Soret et al., 2005). In light of these fi  ndings, we de-
cided to look further at this collection to determine if certain of 
these compounds also inhibit NMD. The underlying idea was 
that such small molecule inhibitors could represent powerful 
tools to decipher the NMD process. In this paper, we report 
the identifi   cation of one such molecule, nonsense-mediated 
mRNA decay inhibitor 1 (NMDI 1), that inhibits nucleus-
associated as well as cytoplasmic NMD. The inhibitory mechanism 
appears to be caused by the loss of the interaction between 
hSMG5 and hUPF1, thereby leading to the stabilization of the 
hyperphosphorylated forms of hUPF1 and to its concentra-
tion in P-bodies. Interestingly, NMDI 1–mediated inhibition 
revealed that other NMD factors and PTC-containing mRNA 
can traffi  c through P-bodies as is the case in yeast (Sheth and 
Parker, 2006).
Results
Identiﬁ  cation of a novel NMD inhibitor
In a previous paper we identifi  ed a series of polycyclic indole 
derivatives that block the function of specifi  c splicing factors 
(Soret et al., 2005). Because certain molecules from this family 
inhibit the function of proteins involved in mRNA maturation, 
we decided to assess their capacity to inhibit NMD. HeLa cells 
were transfected by two test plasmids coding for β globin (Gl) 
and glutathione peroxidase 1 (GPx1) mRNA, either with (Ter) 
or without (Norm) a PTC. Gl mRNA was subject to nucleus-
associated NMD in nonerythroid cells (Thermann et al., 1998; 
Zhang et al., 1998) whereas GPx1 mRNA was subject to cyto-
plasmic NMD (Moriarty et al., 1998). Additionally, a reference 
plasmid coding for the mouse major urinary protein (MUP) 
mRNA was also introduced into the cells (Ishigaki et al., 2001). 
24 h after transfection, cells were incubated for 20 h with 5 μM 
of indole compound (Table S1, available at http://www.jcb.org/
cgi/content/full/jcb.200611086/DC1) or DMSO(−) as a control. 
Then, total RNAs were purifi  ed and analyzed by RT-PCR 
(Fig. 1) to measure NMD effi  ciency. Among the 25 indole de-
rivatives tested, only compound 70 (NMDI 1) stabilized the 
Gl Ter mRNA level about threefold, indicating that this mole-
cule is an inhibitor of nucleus-associated NMD (Fig. 1 A and 
not depicted). Interestingly, NMDI 1 also stabilized the level of 
GPx1 Ter mRNA by approximately twofold (Fig. 1 B and not 
depicted). To confi  rm these results, we measured the NMD in-
hibition by RNase protection assay (RPA), as it represents a 
more reliable approach for RNA quantifi  cation. The results are 
presented in Fig. S1 (A and B) and confi  rm the two- to threefold 
NMD inhibition by NMDI 1. Altogether, these data allowed us to 
conclude that NMDI 1 is an inhibitor of nucleus-associated as 
well as cytoplasmic NMD. Notably, the inhibition level obtained 
with NMDI 1 is similar to that observed with other NMD inhib-
itors such as cycloheximide (CHX) or to the down-regulation of 
hDCP2 or hPARN (Ishigaki et al., 2001; Lejeune et al., 2003). 
To show a more direct correlation between NMDI 1 and NMD 
inhibition, we measured NMD effi  ciency on PTC-containing 
Gl or GPx1 mRNA in cells that were treated with an increasing 
amount of NMDI 1 (Fig. 1 C). Interestingly, we observed a 
progressive NMD inhibition from 0 to 5 μM NMDI 1 for both 
Gl and GPx1 constructs. At >5 μM, we were unable to get a 
substantially stronger inhibition, suggesting that NMD cannot be 
100% eliminated in our experimental conditions or that the 
20–30% of mRNA that escaped from NMD inhibition represents 
the fraction of mRNAs already engaged in the NMD process at 
the time of NMDI 1 treatment. In all subsequent experiments, 
we used 5 μM NMDI 1 as our working concentration. Notably, 
NMDI 1 does not exhibit any cellular toxicity, as measured by 
trypan blue staining, even at concentrations as high as 125 μM 
(unpublished data).
At this stage, some controls were performed to investigate 
the specifi  city of inhibition mediated by NMDI 1. First, NMDI 1 
failed to have any effect on splicing of several pre-mRNA re-
porter transcripts (Soret et al., 2005) and did not affect the level 
of pre-mRNA (Fig. S1, A and B). Second, unlike CHX, which 
inhibits translation, NMDI 1 does not alter the expression of 
transfected fi  refl  y luciferase (Fluc; Fig. 1 D), suggesting that 
NMDI 1 is not a general translation inhibitor. To further dem-
onstrate the absence of any effects of NMDI 1 on translation, 
we performed metabolic labeling of proteins with [
35S]methionine 
in HeLa cells and showed that treatment with NMDI 1 had no 
effect on 
35S incorporation (Fig. S1 C). Third, to assay the integ-
rity of the microRNA (miRNA) decay pathway in the presence PROCESSING BODY COMPONENT DYNAMICS • DURAND ET AL. 1147
of NMDI 1, we used a Renilla luciferase (Rluc) construct that is 
subject to degradation by let- 7 miRNA (pRL-Perf) or immune 
to miRNA decay pathway (pRL-3XBugleMut; Pillai et al., 
2005). Our results indicate that NMDI 1 does not increase 
Renilla activity, which is under the control of let-7 miRNA, 
confi  rming that targeted mRNA degradation by miRNA is not 
altered by NMDI 1 (Fig. 1 E). Finally, we also tested whether 
NMDI 1 could induce the formation of the stress granules that 
provides a sensitive assay for proper mRNA metabolism. 
Indeed, these structures are aggregates of messenger RNPs that 
Figure 1. Identiﬁ  cation of an NMD inhibitor. (A) RT-PCR analysis of globin and MUP mRNA. 10
6 HeLa cells were transfected with a plasmid that codes for 
MUP mRNA and with test and reference plasmids that code for globin mRNA wild type (Norm) or harbor a PTC (Ter). After transfection, cells were incu-
bated with DMSO(−) or 5 μM of a chemical compound for 20 h. Puriﬁ  ed RNA was reverse-transcribed to serve as a substrate for speciﬁ  c ampliﬁ  cation 
by PCR. The three leftmost lanes correspond to serial twofold dilutions of PCR template to ensure that the ampliﬁ  cation conditions are quantitative. (B) RT-PCR 
analysis of GPx1 mRNA wild type (Norm) or cells harboring a PTC (Ter). The experiment was performed as described in A. The measure of the level of 
Gl or GPx1 mRNA was normalized with the level of MUP mRNA. The level of each Gl or GPx1 Ter was normalized with the level of the corresponding 
Gl or GPx1 Norm and is reported as a percentage of Norm (number below each lane). (C) Dose-response effect of NMDI 1 on Gl or GPx1 Ter. Hela cells 
were transfected with pmCMV-Gl Ter or pmCMV-GPx1 Ter and with phCMV-MUP. After 24 h, cells were incubated with an increasing amount of NMDI 1. 
NMD was measured by quantitative radiolabeled RT-PCR and conﬁ  rmed by RPA. (D) Measure of Fluc activity. Cells were transfected with pRLuc and pFluc 
expression vectors, and then treated with DMSO(−), NMDI 1, or CHX. Fluc activity was measured by a luminometer and normalized according to the 
expression level of Fluc and Rluc mRNA. (E) NMDI 1 does not inhibit miRNA-induced mRNA decay. HeLa cells were transfected with either pRL-3XBulgeMut 
(RLm) or pRL-Perf (RLp; Pillai et al., 2005) and incubated for 24 h with DMSO(−) or NMDI 1. Histogram represents the ratio of Rluc/Fluc. Results were 
normalized to RLm, which was set at 10 arbitrary units. All results are representative of at least three independent experiments. Error bar denotes SD.JCB • VOLUME 178 • NUMBER 7 • 2007  1148
form when cells are subjected to several stresses, including mild 
translational inhibition. Unlike sodium arsenite treatment that is 
commonly used to induce stress granule formation (Kedersha 
et al., 2005), NMDI 1 treatment did not change the localization 
of G3BP protein, a well-characterized marker of stress granules 
(Fig S1 D; Tourriere et al., 2003). Collectively, these results in-
dicate that NMDI 1 is a new and specifi  c NMD inhibitor.
NMDI 1 abrogates NMD upstream 
of hUPF1 functions
To gain insight into the mode of inhibition of NMDI 1, we ana-
lyzed its effects on a tethering system that mimics the sequen-
tial recruitment of NMD factors on mRNA (Lykke-Andersen 
et al., 2000; Kim et al., 2005). Cells were transfected with two 
types of constructs. The fi  rst codes for a Fluc mRNA contain-
ing eight binding sites for the MS2 protein in its 3′ untranslated 
region and the second codes for either the MS2 protein or one 
of the following fusions: MS2-hUPF1, MS2-hUPF2, or MS2-
hUPF3X. Additionally, we transfected HeLa cells with a con-
struct coding for the Rluc mRNA to normalize the amount of 
analyzed RNA. Cells were then incubated for 20 h with NMDI 1 
or DMSO(−) as a negative control, and Rluc as well as Fluc 
mRNA levels were measured by RT-PCR as described previ-
ously (Hosoda et al., 2005). The expression of each MS2 fusion 
was controlled by Western blot to verify that the observed ef-
fects were not caused by a variation in protein expression (Fig. 
2 A). In each case, the compound did not affect expression of 
the MS2 fusion, which was itself never higher than the level of 
the endogenous protein. As expected, the control experiment 
performed in the presence of DMSO revealed that the level 
of Fluc mRNA was lower in cells expressing one of the MS2-
hUPF fusion proteins compared with cells expressing only MS2 
(Fig. 2 B). Remarkably, NMDI 1 counteracted the degradation 
induced by MS2-hUPF2 or MS2-hUPF3X but had no effect 
against MS2-hUPF1 (Fig. 2 B). Notably, the inhibition levels 
obtained with NMDI 1 were very similar to those observed 
when NMD was inhibited through down-regulation of hCBP80 
(Hosoda et al., 2005). To obtain a more accurate measure of the 
NMD inhibition, Rluc and Fluc mRNA levels were also mea-
sured by RPA. The results are presented in Fig. S2 A (available 
at http://www.jcb.org/cgi/content/full/jcb.200611086/DC1) 
and reproduce the quantifi  cation of mRNA levels by RT-PCR 
(Fig. 2 B). Altogether, these results indicate that NMDI 1 inhibits 
NMD downstream of hUPF3X or hUPF2 recruitment and up-
stream of hUPF1 functions.
NMDI 1 does not prevent the interactions 
between hUPF1 and hUPF3X
In the light of the results described in the previous paragraph, 
we hypothesized that NMDI 1 could prevent the recruitment of 
hUPF1 to the EJC via its interactions with the other hUPF 
proteins. To test this, we immunoprecipitated hUPF1 from HeLa 
cell extracts under conditions that preserve the integrity of mes-
senger RNPs (Lejeune and Maquat, 2004). NMDI 1 or DMSO(−) 
was added to the cell culture 20 h before immunoprecipitation (IP). 
Because hUPF2 was shown to be dispensable in some NMD 
cases (Gehring et al., 2005), we focused our analysis on the 
presence of hUPF3X protein in each IP (Fig. 3 A). As a control 
for IP specifi  city, we did not detect tubulin protein in any of the 
hUPF1 IPs and no proteins were present in the IP performed 
with normal rabbit serum. The results show that hUPF3X was 
present in hUPF1 IP even when cells were incubated with our 
NMD inhibitor. Thus, these data demonstrate that the interaction 
between hUPF1 and hUPF3X is not abolished by NMDI 1 and 
suggest that NMDI 1 would not prevent the recruitment of hUPF1 
to the EJC.
NMDI 1 stabilizes hyperphosphorylated 
forms of hUPF1
Because hUPF1 requires a cycle of phosphorylation and de-
phosphorylation during NMD (Ohnishi et al., 2003), we next 
investigated the possibility that NMDI 1 may affect hUPF1 
function by interfering with its phosphorylation level. We thus 
measured the level of hUPF1 phosphorylation in cells incu-
bated with NMDI 1 or, as a control, with DMSO(−) by 2D gel 
analysis. Because hUPF1 phosphorylation is influenced by 
serum (Pal et al., 2001), we used 293T cells that, unlike HeLa 
cells, can be synchronized by serum deprivation. Cells were 
transfected with the expression vector pCI-neo-FLAG-hUpf1 
Figure 2.  NMDI 1 inhibits NMD before the functions of hUPF1. (A) HeLa 
cells were transiently transfected with plasmids that encode the Rluc mRNA, 
the Fluc mRNA containing MS2 binding sites in its 3′ untranslated region, 
and the mRNA coding for MS2 protein either alone or fused with one of 
the hUPF proteins. 24 h after transfection, HeLa cells were incubated either 
with DMSO(−) or NMDI 1 for 20 h. The expression level of each MS2 fu-
sion protein was determined by Western blot. 10 μg of protein extract was 
loaded on 10% SDS–polyacrylamide gel and transferred to a nitrocellu-
lose membrane before incubation with antibodies against each of the hUPF 
proteins. The position of endogenous and exogenous proteins is indicated 
on the right. (B) The level of Fluc mRNA was normalized with the level of 
the corresponding Rluc mRNA and is reported as a percentage of normal-
ized Fluc mRNA when only MS2 protein was expressed. The three leftmost 
lanes correspond to serial twofold dilutions of PCR template to show that 
the ampliﬁ  cation conditions are quantitative.PROCESSING BODY COMPONENT DYNAMICS • DURAND ET AL. 1149
(Sun et al., 1998) and synchronized for 24 h by serum depriva-
tion 12 h after transfection. Finally DMSO or 5 μM NMDI 1 
was added for 3 h before adding back serum for 1 h. Our results 
show that when serum was not added back to the cell culture, 
the FLAG-hUPF1 protein electrofocalized in one spot corre-
sponding to the unphosphorylated protein (Fig. 3 B; Pal et al., 
2001). After serum addition, we observed a mild phosphoryl-
ation of FLAG-hUPF1 protein in the presence of DMSO and 
the stabilization of hyperphosphorylated isoforms of FLAG-
hUPF1 when cells were incubated with NMDI 1 (Fig. 3 B). 
We concluded that NMDI 1 stabilized hyperphosphorylated 
isoforms of hUPF1.
As it has been proposed that hUPF1 would localize to 
P-bodies when hyperphosphorylated (Unterholzner and Izaurralde, 
2004; Fukuhara et al., 2005), we analyzed the cellular local-
ization of FLAG-hUPF1 in HeLa cells in the absence or pres-
ence of NMDI 1 (Fig. 3 C). With the exception of coexpression 
experiments with hSMG7, which induces the recruitment of 
hUPF1 to P-bodies (Fig. 3 C; Unterholzner and Izaurralde, 
2004), exogenous hUPF1 was equally distributed through the 
cytoplasm when cells were incubated with DMSO(−) as previ-
ously reported for untreated cells (Fig. 3 C; Lykke-Andersen 
et al., 2000; Mendell et al., 2002). When cells were treated with 
NMDI 1, we observed cytoplasmic concentrations of FLAG-
hUPF1 in some structures that colocalize with the three com-
monly used markers of P-bodies: GFP-GE1, YFP-hSMG7, or 
CFP-hDCP1a (Fig. 3 C). We also verifi  ed that FLAG-hUPF1 
accumulated in P-bodies in the presence of NMDI 1 in 293T 
cells under the same experimental conditions used to study the 
phosphorylation level of FLAG-hUPF1 (Fig. S2 B). We used 
hXRN1 protein as a P-body marker to avoid any additional 
transfected DNA. After addition of serum, we observed some 
FLAG-hUPF1 cytoplasmic concentrations that colocalize with 
hXRN1 only when cells were treated with NMDI 1 but not in 
its absence. To defi  nitively demonstrate that hyperphosphory-
lated isoform of hUPF1 accumulates in P-bodies, HeLa cells 
were treated for 20 h with either DMSO(−) or NMDI 1, and the 
cellular localization of endogenous phosphorylated hUPF1 
was determined using a specifi  c antibody raised against a phos-
phoepitope of this protein (Ohnishi et al., 2003). The results 
presented in Fig. S3 (available at http://www.jcb.org/cgi/content/
full/jcb.200611086/DC1) indicate that in the presence of NMDI 1, 
phosphorylated hUPF1 isoforms colocalize with CFP-hDCP1a 
foci. We conclude that NMDI 1 induces the accumulation of 
hyperphosphorylated hUPF1 isoforms in P-bodies. This may 
occur either via stimulation of phosphorylation or by blocking 
dephosphorylation.
To distinguish between these two possibilities, we sub-
sequently investigated the association of hUPF1 with other NMD 
partners in HeLa cells treated or untreated with NMDI 1 (Fig. 
3 A). We fi  rst analyzed the interaction of hUPF1 with its dephos-
phorylation complex. Immunoprecipitation of hUPF1 allowed 
recovery of hSMG5, hSMG6, and hSMG7 from DMSO-treated 
cells. However, after treatment of HeLa cells with NMDI 1 
only hSMG6 and hSMG7 but not hSMG5 were still associated 
with hUPF1 (Fig. 3 A). Thus, we conclude that NMDI 1 destabi-
lizes the interaction between hUPF1 and hSMG5. The fact that 
NMDI 1 does not alter the association of hUPF1 with hSMG1 
and hUPF3X strongly suggests that NMDI 1 does not infl  uence 
the interactions between hUPF1 and its phosphorylation com-
plex (Fig. 3 A). Altogether, our results indicate that the hyper-
phosphorylation of hUPF1 is most likely caused by a failure in 
dephosphorylation because of the loss of interaction between 
hUPF1 and hSMG5 rather than an activation of phosphor-
ylation. This conclusion is consistent with fi  ndings showing 
that hSMG5 is essential for hUPF1 dephosphorylation (Ohnishi 
et al., 2003).
hSMG5 is excluded from P-bodies 
in the presence of NMDI 1
Because NMDI 1 induces the localization of hUPF1 in P-bodies, 
hUPF1 hyperphosphorylation, and the destabilization of inter-
actions between hUPF1 and hSMG5, we assessed the cellular 
localization of the hUPF1 dephosphorylation complex during 
NMDI 1 treatment. hSMG5 and hSMG7 have been shown to 
localize mainly in the cytoplasm and particularly in P-bodies 
as shown by colocalization experiments with the endogenous 
LSM4 for hSMG7 and with hSMG7 for hSMG5 (Unterholzner 
and Izaurralde, 2004). hSMG6 similarly localizes mainly in the 
cytoplasm and also in some cytoplasmic foci that do not con-
tain endogenous LSM4 (Unterholzner and Izaurralde, 2004). 
We transfected HeLa cells with expression vectors encoding 
YFP-hSMG5, YFP-hSMG6, or YFP-hSMG7 (Unterholzner 
and Izaurralde, 2004) and CFP-hDCP1a as a P-body marker. 
After 24 h, we added DMSO(−) or 5 μM NMDI 1 to the cells. 
As previously shown, in the absence of the inhibitor, YFP-
hSMG5, YFP-hSMG6, and YFP-hSMG7 were concentrated in 
cytoplasmic foci (Unterholzner and Izaurralde, 2004; Fukuhara 
et al., 2005), which, for a substantial fraction of them (33, 72, 
and 100%, respectively), colocalized with CFP-hDCP1a (Fig. 
3 D). The fact that we observed hSMG6 in P-bodies unlike what 
was previously observed (Unterholzner and Izaurralde, 2004) 
was likely caused by the different markers used for detection of 
P-bodies and may refl  ect heterogeneity of P-bodies in their pro-
tein composition (see Discussion). In the presence of NMDI 1, 
the cytoplasmic foci containing YFP-hSMG6 or YFP-hSMG7 
perfectly colocalized with CFP-hDCP1a P-bodies. Interest-
ingly, hSMG5 was no longer observed in cytoplasmic foci and 
became evenly distributed in the cytoplasm in cells treated with 
NMDI 1 (Fig. 3 D).
Endogenous hSMG5, hSMG6, or hSMG7 cannot be de-
tected in cytoplasmic foci because of their weak expression 
(Unterholzner and Izaurralde, 2004). Because NMDI 1 inhibits 
NMD and induces the accumulation of hUPF1 in P-bodies as 
shown with exogenous as well as endogenous hUPF1 (Figs. 3 C, 
S2 B, and S3), we tested whether the three hSMG proteins 
would also accumulate in cytoplasmic foci of treated cells. 
The results shown in Fig. S3 indicated that these three pro-
teins were not detected in cytoplasmic foci in DMSO-treated 
cells. However, when cells were incubated with NMDI 1, 
both hSMG6 and hSMG7 colocalized with CFP-hDCP1a in 
P-bodies. In agreement with the transfection experiment (Fig. 
3 D) under the same conditions, hSMG5 was not detected in 
cytoplasmic foci. Altogether, our results indicate that NMDI 1 JCB • VOLUME 178 • NUMBER 7 • 2007  1150
Figure 3.  NMDI 1 modiﬁ  es the cellular distribution of hUPF proteins and stabilizes hyperphosphorylated isoforms of FLAG-hUPF1. (A) Endogenous hUPF1 
protein was immunopuriﬁ  ed using rabbit anti-hUPF1 antibodies from HeLa cell extracts that were incubated with DMSO(−) or 5 μM NMDI 1(+). In parallel, 
an immunopuriﬁ  cation control was performed using normal rabbit serum to verify the speciﬁ  city of the immunopuriﬁ  cation protocol. The three leftmost lanes cor-
respond to serial twofold dilutions of a whole HeLa cell extract. The asterisk marks an uncharacterized band that presumably represents a degradation product. 
(B) 2D gel analysis of the FLAG-hUPF1 phosphorylation level. 10
6 293T cells were transfected with 1 μg pCI-neo-FLAG-hUPF1 plasmid. 12 h later, the serum was 
removed from the culture medium for 24 h, and then either DMSO or 5 μM NMDI 1 was added to the culture medium for 3 h before adding back 10% serum 
(sample (−+) except in sample (−−)). Proteins were extracted and loaded on a 2D gel analysis system (see Materials and methods). (C) Immunoﬂ  uorescence 
assay. HeLa cells were transfected with pCI-neo-FLAG-hUpf1 and either pYFP-hSmg7, pGFP-Ge1, or pCFP-hDcp1a. 24 h after transfection, cells were incubated 
with DMSO(−) or 5 μM NMDI 1 for 20 h. The blue staining visible in the merge of the two leftmost set of images corresponds to nuclei staining by Hoechst stain. 
(D) Immunoﬂ  uorescence assay. HeLa cells were transfected with pYFP-hSmg5, pYFP-hSmg6, or pYFP-hSmg7 and with pCFP-hDcp1a expression vectors. 24 h after 
transfection, cells were cultured in the presence of DMSO(−) or 5 μM NMDI 1 for 20 h. The white squares are magniﬁ  cations of cell areas. Bars, 10 μm.PROCESSING BODY COMPONENT DYNAMICS • DURAND ET AL. 1151
modifi  es the cellular localization of hSMG5 by excluding it 
from P-bodies. This is consistent with the failure of hUPF1 anti-
bodies to immunoprecipitate hSMG5 from NMDI 1–treated 
cells (Fig. 3 A).
hUPF3 and hUPF3X localize in P-bodies 
when NMD is blocked by NMDI 1
Because some NMD factors such as hUPF1, hSMG5, hSMG6, 
or hSMG7 localize to P-bodies (Unterholzner and Izaurralde, 
2004, this paper) we envisaged that other NMD factors may 
pass through P-bodies in a transient manner. As NMDI 1 is able 
to block NMD at a step where hUPF1 is confi  ned to P-bodies, 
we investigated the cellular localization of hUPF3 and hUPF3X 
in both treated and untreated cells. These two proteins have been 
previously shown to be primarily nuclear proteins in untreated 
cells (Serin et al., 2001). We transfected HeLa cells with 
expression vectors that code for hUPF3-FLAG or hUPF3X-
FLAG together with one of the P-body markers YFP-hSMG6, 
YFP-hSMG7, GFP-GE1, or CFP-hDCP1a. The cells were 
treated with DMSO or NMDI 1 before we performed indirect 
immunofl  uorescence experiments (Fig. 4 and not depicted for 
CFP-hDCP1a). As for untreated cells (Lykke-Andersen et al., 
2000; Serin et al., 2001), hUPF3 or hUPF3X localized primar-
ily in the nucleus when cells were incubated with DMSO(−) 
(Fig. 4). However, when cells were grown in the presence 
of NMDI 1, we observed a cytoplasmic localization of hUPF3 
as well as hUPF3X, with some accumulation in foci. To fur-
ther characterize these foci, we analyzed their colocalization 
with cotransfected P-body markers (Fig. 4 and not depicted). 
hUPF3-FLAG as well as hUPF3X-FLAG proteins colocalized 
with YFP-hSMG6 (68 and 57%, respectively) or YFP-hSMG7 
(50 and 51%, respectively) in cells treated with NMDI 1. 
Surprisingly, unlike with FLAG-hUPF1, GFP-GE1 did not co-
localize with hUPF3-FLAG or hUPF3X-FLAG. We conclude 
that hUPF3/3X proteins can translocate to the cytoplasm, 
which is consistent with their shuttling properties (Lykke-
Andersen et al., 2000; Serin et al., 2001), and can reach a 
subset of P-bodies.
Figure 4.  hUPF3 localizes to P-bodies when NMD is inhibited. HeLa cells were transfected with a pcDNA3-hUpf3-FLAG or pcDNA3-hUpf3X-FLAG plasmid 
and either pGFP-Ge1, pYFP-hSmg6, or pYFP-hSmg7. 24 h after transfection, cells were incubated either with DMSO(−) or with 5 μM NMDI 1 for 20 h. In the 
merge, nuclei are visualized by Hoechst staining in blue. The white squares are magniﬁ  cations of cell areas. Bars, 10 μm.JCB • VOLUME 178 • NUMBER 7 • 2007  1152
PTC-containing mRNAs accumulate 
in P-bodies in the presence of NMDI 1
Because NMD factors accumulate in P-bodies when NMD is 
inhibited, we were interested in determining whether NMD sub-
strates also accumulate in P-bodies. In yeast, it has recently been 
shown that PTC-containing mRNAs accumulate in P-bodies 
when NMD is blocked (Sheth and Parker, 2006). We speculated 
that our NMD inhibitor would allow us to reach the same con-
clusion in mammalian cells. HeLa cells were transfected with 
pmCMV-Gl Ter or pmCMV-GPx1 Ter and the localization 
of the resulting mRNAs was analyzed with several P-body 
markers: GFP-GE1, YFP-hSMG6, YFP-hSMG7, CFP-hDCP1a, 
GFP-hCCR4, FLAG-hUPF1, hUPF3-FLAG, or hUPF3X-FLAG 
(Figs. 5 and S4, available at http://www.jcb.org/cgi/content/full/
jcb.200611086/DC1). As expected, in the absence of the inhibitor 
we were unable to detect PTC-containing mRNAs, most likely 
because of their rapid decay by NMD. However, in the presence 
of NMDI 1, PTC-containing mRNAs were stabilized and de-
tected mainly in cytoplasmic aggregates. Interestingly, our results 
indicated a substantial colocalization between PTC-containing 
Gl or GPx1 mRNA and each tagged version of the tested hUPF 
proteins CFP-hDCP1a, YFP-hSMG6, or YFP-hSMG7 (Figs. 5 A 
and S4). Although the colocalization between Gl Ter or GPx1 
Ter mRNAs and hUPF3/3X was total (Fig. 5 and not depicted for 
hUPF3X), it was only partial with other P-body components such 
as FLAG-hUPF1 (63 and 74%, respectively), YFP-hSMG6 (76 
and 81%, respectively), or YFP-hSMG7 (71 and 94%, respec-
tively), and infrequently with GFP-hCCR4 (11 and 33%, respec-
tively; Figs. 5 A and S4). Notably, we often observed that RNA 
foci and P-bodies did not overlap perfectly. Additionally, we 
were unable to observe a colocalization between PTC-containing 
mRNAs and GFP-GE1 (Figs. 5 A and S4). Altogether, our results 
show that PTC-containing mRNAs were present in and adjacent 
to P-bodies when NMD was inhibited by NMDI 1. In addition, 
these data indicate heterogeneity in the composition of P-bodies 
because some markers colocalize with PTC-containing mRNAs 
while others do not.
The accumulation of PTC-containing mRNAs in P-bodies 
when NMD is blocked in mammalian cells was confi  rmed by 
a more resolutive approach in U2OS cells. In this setting, we 
tagged the mRNA with a 24× MS2 binding site repeat because 
this approach can effi  ciently detect single mRNA molecules by in 
situ hybridization (Fusco et al., 2003; Fig. 5 B). In control cells, 
PTC-containing mRNAs were mostly detected in the nucleus, 
and the cytoplasmic molecules that were detected did not accu-
mulate in P-bodies labeled with CFP-hDCP1a. When NMD was 
inhibited with NMDI 1, higher levels of Gl-Ter MS2 mRNAs 
were detected in the cytoplasm, and these molecules accumulated 
in structures that colocalized with P-bodies. As previously ob-
served, mRNAs did not perfectly colocalize with CFP-hDCP1a, 
but were instead adjacent and formed a ring at the periphery of 
P-bodies, similar to what was found with miRNA targets (Pillai 
et al., 2005). These data confi  rmed that mRNAs subjected to 
NMD accumulate in P-bodies when their degradation is inhibited, 
and this conclusion seems not be cell type specifi  c.
We also analyzed the localization of Gl or GPx1 Norm 
mRNAs in HeLa and U2OS cells treated with NMDI 1 (Fig. 6). 
Our results showed no specifi  c accumulation of these mRNAs 
in cytoplasmic bodies typifi  ed by YFP-hSMG6, GFP-GE1, or 
CFP-hDCP1a in the presence of NMDI 1. In contrast,  we did 
not see any wild-type mRNAs in P-bodies either because Norm 
mRNAs do not go to P-bodies or because their degradation 
pathway is not affected by either DMSO or NMDI 1. These 
results support the idea that NMDI 1 is an NMD inhibitor rather 
than a general RNA decay inhibitor.
Only some steps of the NMD process 
occur in P-bodies
To determine whether the accumulation of NMD factors in 
P-bodies can be triggered when any step of the NMD process 
is inhibited, we decided to interfere with the NMD process in 
three different ways. The fi  rst one relies on the down-regulation 
of hUPF2 using siRNA (Kim et al., 2005; Fig. 7 A). According to 
the current model of NMD in mammalian cells (Maquat, 2004b), 
depletion of hUPF2 will block NMD at an earlier step than the 
one induced by NMDI 1. Interestingly, hUPF2 down-regulation 
does not induce the accumulation of FLAG-hUPF1, hUPF3-
FLAG, or hUPF3X-FLAG P-bodies. Additionally, whereas 
hUPF2 depletion induces a stabilization of Gl-Ter mRNA be-
cause of the inhibition of NMD, Gl-Ter mRNA was homo-
genously distributed in the cytoplasm with no accumulation in 
P-bodies (Fig. 7 B). Thus, inhibition of NMD by hUPF2 deple-
tion does not trigger accumulation of NMD factors and sub-
strates in P-bodies.
The second one is based on the down-regulation by siRNA 
of a protein involved in a late step of the NMD process such as 
hXRN1 (Cougot et al., 2004; Fig. 7 C). As for the down-regulation 
of hUPF2, the cellular localization of NMD factors including 
FLAG-hUPF1 or hUPF3-FLAG was not modifi  ed by the cellu-
lar lack of the hXRN1 protein (Fig. 7 D), whereas Gl-Ter RNA 
was detected in P-bodies. This result may indicate that the re-
cycling of NMD factors had already occurred before the function 
of hXRN1. We conclude that the presence of NMD factors in 
P-bodies depends on the NMD step, i.e., only some steps in the 
NMD process occur in P-bodies.
 According to our results, hUPF1 dephosphorylation is 
one of the NMD steps that occur in P-bodies. In the presence 
of NMDI 1, NMD is inhibited because hUPF1 is stalled in a 
hyperphosphorylated form caused by the release of hSMG5 
from P-bodies. To further confi  rm this model, we aimed to 
mimic the effect of NMDI 1 by analyzing the cellular local-
ization of NMD factors in the presence of the hUPF1 mutant 
protein (HA-hUPF1dNT) that has been shown to prevent its 
interaction with hSMG5 because it lacks an N- terminal, or in 
the presence of hSMG5 mutant proteins (HA-hSMG5dCT 
and HA-hSMG5DA) that cannot dephosphorylate hUPF1 be-
cause of either the lack of a C-terminal or the substitution 
of aspartic acid 860 by an alanine (Ohnishi et al., 2003). As 
shown in Fig. 8 A, when HeLa cells express HA-hUPF1dNT 
protein, hUPF3-FLAG, hUPF3X-FLAG proteins, Gl Ter, and 
GPx1 Ter mRNA localize to P-bodies as shown by the co-
localization with CFP-hDCP1a. This result is similar to what 
we observed when cells were treated with NMDI 1. Interest-
ingly, YFP-hSMG5 was not detected in P-bodies, suggesting PROCESSING BODY COMPONENT DYNAMICS • DURAND ET AL. 1153
Figure 5.  PTC-containing mRNAs accumulate in P-Bodies under conditions of NMD inhibition. (Α) HeLa cells were transfected with pmCMV-Gl Ter and an 
expression vector encoding a P-body component: pCI-neo-FLAG-hUpf1, pYFP-hSmg6, pYFP-hSmg7, pcDNA3-hUpf3-FLAG, pGFP-Ge1, or pGFP-hCcr4. 24 h 
after transfection, DMSO(−) or 5 μM NMDI 1 was added to the culture medium for 20 h. (B) U2OS cells were transfected with a pGl-Ter MS2 plasmid and 
a pCFP-hDcp1a expression vector. These cells were used for their tendency to highly express transfected genes, which is crucial for this approach. Cells were 
treated as described in A. Nuclei are shown in the merge by Hoechst staining in blue. The white squares are magniﬁ  cations of cell areas. Bars, 10 μm.JCB • VOLUME 178 • NUMBER 7 • 2007  1154
that by destabilizing the interaction between hSMG5 and hUPF1, 
hSMG5 is excluded from P-bodies. Additionally, expression of 
either HA-SMG5dCT or HA-SMG5DA induced accumulation 
of FLAG-hUPF1, hUPF3-FLAG, hUPF3X-FLAG proteins, 
Gl Ter, and GPx1 Ter mRNA into P-bodies (Fig. 8, B and C, 
respectively). Thus, by specifi  cally blocking the dephosphor-
ylation of hUPF1, NMD factors and substrates concentrate 
into P-bodies.
Figure 6.  Wild-type mRNAs do not accumulate in 
P-bodies when NMD is inhibited by NMDI 1. (A) HeLa 
cells were transfected with pmCMV-Gl Norm and an 
expression vector encoding a P-body component: pYFP-
hSmg6 or pGFP-Ge1. Cells were submitted to the same 
treatment as in Fig. 5 A. (B) Same as in Fig. 5 B except 
that cells were transfected with a pGl Norm MS2 plas-
mid rather than pGl-Ter MS2. The white squares are 
magniﬁ  cations of cell areas. Bars, 10 μm.PROCESSING BODY COMPONENT DYNAMICS • DURAND ET AL. 1155
Discussion
In this study, we have characterized an indole derivative, NMDI 1, 
as an NMD inhibitor. This molecule has allowed us to study 
specifi  c steps of NMD. The power of this approach lies in the 
ability to freeze NMD at a step when hUPF1 and hUPF3/3X are 
detected in P-bodies (Figs. 3 and 4). Using biochemical and cel-
lular biology approaches, we have determined the precise event 
blocked by NMDI 1 and established that this inhibitor prevents 
the interactions between hUPF1 and hSMG5, resulting in the 
subsequent exclusion of hSMG5 from P-bodies and the stabili-
zation of hyperphosphorylated isoforms of hUPF1. Unlike other 
approaches, such as transfection-mediated down-regulation of 
NMD factors, where only a fraction of cells are subject to the 
inhibition of NMD, small chemical molecules have the ability 
to diffuse across the cell membrane and affect most cells in 
culture. Therefore, such inhibitors should enable NMD to be 
inhibited in more physiologically complex environments such 
as tissue or multicellular organisms to study NMD mechanism 
in vivo and to evaluate their potential therapeutic capacities 
(Kuzmiak and Maquat, 2006).
As in yeast (Sheth and Parker, 2006), PTC-containing 
mRNAs, hUPF1, and hUPF3/3X proteins are found in P-bodies 
of mammalian cells when NMD is prevented (Figs. 4, 5, and 8). 
Figure 7.  Down-regulation of hUPF2 or hXRN1 does not lead to the accumulation of NMD factors in P-bodies. (A and C) The efﬁ  ciency of the hUPF2 (A) 
or hXRN1 (C) down-regulation was evaluated by Western blot from 10 μg of total protein. The three leftmost lanes represent 2× dilutions of total extract 
from HeLa cells that were not transfected. (B) HeLa cells were transfected with pCFP-hDcp1a and either pCI-neo-FLAG-hUPF1, pcDNA3-hUPF3-FLAG, 
pcDNA3-hUPF3X-FLAG, or pmCMV-Gl Ter in the presence of siRNA luciferase (Luc) or siRNA hUPF2 (Upf2). (D) Same as B except siRNA hXRN1 replaced 
siRNA hUPF2, and pcDNA3-hUPF3X-FLAG was not tested. The white squares are magniﬁ  cations of cell areas. Bars, 10 μm.JCB • VOLUME 178 • NUMBER 7 • 2007  1156
Figure 8.  NMDI 1 effect on the localization of NMD factors and substrates can be reproduced by using hUPF1 or hSMG5 mutants that prevent the 
phosphorylation of hUPF1. HeLa cells were transfected with pCFP-hDcp1a and pHA-hUpf1dNT (A), pHA-hSmg5dCT (B) or pHA-hSmg5DA (C), and either 
pCI-neo-FLAG-hUpf1, pcDNA3-hUpf3-FLAG, pcDNA3-hUpf3X-FLAG, pmCMV-Gl-Ter, pmCMV-GPx1-Ter, pYFP-hSmg5 (A), or pCI-neo-FLAG-hUpf1 (B and C). 
The white squares are magniﬁ  cations of cell areas. Bars, 10 μm.PROCESSING BODY COMPONENT DYNAMICS • DURAND ET AL. 1157
Undoubtedly, yeast and human P-bodies share some similarities 
in their protein compositions and functions but clear differences 
can also be seen. Unlike in yeast, in mammalian cells PTC-
containing mRNAs accumulate in P-bodies, or more precisely 
at the periphery of P-bodies, suggesting that P-bodies can be 
formed by several compartments. This observation is consistent 
with a recent paper (Pillai et al., 2005) showing that RNA can 
be localized at the periphery of P-bodies where it might be 
stored before being degraded or released from the P-bodies. 
Another difference between yeast and mammalian P-bodies is 
that a down-regulation of hUPF2 in mammals does not lead to 
the accumulation of hUPF1 into P-bodies (Fig. 7) as it does in 
yeast (Sheth and Parker, 2006). Our results suggest that hUPF2 
is involved in the NMD process before the transit of NMD fac-
tors and substrates through P-bodies. These differences likely 
refl  ect a divergence in the process of NMD in yeast and in mam-
malian cells. Surprisingly, when we blocked NMD at a late step 
when RNAs are going to be degraded, (i.e., by down-regulating 
hXRN1) we did not detect NMD factors in P-bodies but we did 
observe PTC-containing mRNAs in P-bodies (Fig. 7). This con-
fi  rms that NMD involves traffi  cking to P-bodies and suggests 
that by inhibiting the RNA degradation step, we did not prevent 
the recycling of NMD factors from P-bodies.
 Interestingly, we did not observe any differences in the 
cellular distribution and in the protein composition between 
P-bodies containing Gl Ter mRNA and those containing GPx1 
Ter mRNA, even though these two mRNAs are subject to 
nucleus-associated or cytoplasmic NMD, respectively. However, 
we cannot exclude the possibility that NMDI 1 would freeze a 
series of dynamic events that occurs during NMD and that this 
would induce a drift of nucleus-associated P-bodies to the cyto-
plasm. It is also possible that P-bodies with nucleus-associated 
NMD substrates and P-bodies with cytoplasmic NMD sub-
strates have different biochemical or physical properties that 
would lead to the cosedimentation of one with the nuclear frac-
tion and of the other with the cytoplasmic fraction. Further 
investigations will be necessary to clarify this point.
NMDI 1 allowed us to show that P-bodies display a 
large degree of variability in their NMD factor composition. 
For example, whereas hSMG6 colocalizes with CFP-hDCP1a 
or FLAG-hUPF1 when NMD is inhibited (Fig. 3 and not de-
picted), it only shows a partial overlap with CFP-hDCP1a in 
DMSO-treated cells (Fig. 3) and no colocalization with LSM4 
(Unterholzner and Izaurralde, 2004). As another example, we 
detected hUPF3/3X-FLAG proteins in P-bodies positive for 
YFP-hSMG6 or YFP-hSMG7 but not in P-bodies containing 
GFP-GE1 (Fig. 4). Similarly, PTC-containing mRNA is found 
in all P-bodies holding hUPF3/3X-FLAG proteins and in most 
P-bodies containing FLAG-hUPF1, YFP-hSMG6, or YFP-hSMG7, 
but rarely or never in P-bodies stained with GFP-hCCR4 or 
GFP-GE1 (Figs. 5 and S4). Because the factors that do not 
colocalize upon NMDI 1 treatment, such as hUPF3/3X (or PTC-
containing mRNAs) and GE1, still form foci that colocalize with 
other P-body markers (such as hSMG7), these data suggest that 
P-bodies can exist in several “fl  avors” or forms that would dif-
fer in protein composition (at least in mammalian cells). These 
variations in P-body composition could refl  ect different func-
tional states. In this view, hUPF3/3X, hSMG6, hSMG7, hUPF1, 
and hDCP1a would be involved at early steps of RNA process-
ing in P-bodies or, as has been recently proposed, would nucle-
ate the formation of P-bodies on the PTC-containing mRNA 
(Franks and Lykke-Andersen, 2007). hCCR4 would then join 
the structure, followed by GE1 that would induce degradation 
of the PTC-containing mRNA and recycling of hUPF3/3X. 
Then other NMD factors are recycled for a new turn of NMD 
(Fig. 9). This evolution in P-body composition could arise by 
fusion of different subcategories of P-bodies, by the shuttling of 
individual components, or by a combination of these processes. 
An attractive approach to answer these questions would be to 
characterize NMD inhibitors that target other steps than the de-
phosphorylation of hUPF1.
Materials and methods
All results presented in this article are representative from at least three 
independent experiments.
Chemical molecules library
All the polycyclic indole compounds studied in this paper issue from the 
Institut Curie–Centre National de la Recherche Scientiﬁ  que  compound 
library. Each compound was suspended at 20 mg/ml in DMSO and then 
prepared at a 5-μM working dilution in 10% DMSO (vol/vol). The synthe-
sis and the puriﬁ  cation of these compounds has been described previously 
(Rivalle et al., 1981).
Constructs
Gl Norm and Ter fused to MS2 binding sites constructs (Figs. 5 B and 6 B) 
were obtained by PCR ampliﬁ  cation from Gl wild-type and NS39 constructs 
(provided by M. Hentze and N. Gehring, European Molecular Biology 
Laboratory, Heidelberg, Germany; Thermann et al., 1998) using a sense 
Figure 9.  A model of P-body composition 
dynamics. (1) At the early stage, phosphorylated 
hUPF1, hUPF3/3X, hSMG5, hSMG6, hSMG7, 
and PTC-containing mRNAs transit to P-bodies. 
(2) hCCR4 accumulates later, followed by 
GE1, which induces the degradation of PTC-
containing mRNAs, and (3) the recycling of 
hUPF3/3X. Finally, other NMD factors will be 
recycled, in particular hUPF1.JCB • VOLUME 178 • NUMBER 7 • 2007  1158
primer (5′-G  C  A  A  C  C  T  C  A  A  G  C  T  T  A  C  A  C  C  A  T  G  G  T  G  C  A  C  C  T  G  A  C  -3′) and an 
antisense primer (5′-A  G  A  A  A  G  C  A  G  A  T  C  T  G  C  T  T  A  G  T  G  A  T  A  C  T  T    G  T  G  -3′). 
The ampliﬁ  ed fragment was cloned in HindIII–BglII of a modiﬁ  ed pRSVbgal 
plasmid containing 24× MS2 sites (Fusco et al., 2003).
NMD measurements by RT-PCR
HeLa cells were cultured in 60-mm dishes in DME (Invitrogen) supplemented 
with 10% (vol/vol) fetal bovine serum at 37°C and 5% CO2. 10
6 cells 
were cotransfected with 3 μg of test plasmid pmCMV-Gl (Norm or 39Ter; 
Sun et al., 1998) or 3 μg of test plasmid pmCMV-GPx1 (Norm or 46Ter; 
Moriarty et al., 1998) and 1 μg of reference plasmid phCMV-MUP (all 
provided by L. Maquat, University of Rochester, Rochester, NY; Belgrader 
and Maquat, 1994) using Lipofectamine Plus reagent (Invitrogen) accord-
ing to the manufacturer’s instructions. 24 h after transfection, cells were 
treated for 20 h with 5 μM of chemical molecules or 0.01% DMSO 
(vol/vol) as a control. Total RNA was puriﬁ  ed using the TRI reagent (Sigma-
Aldrich), and Gl, GPx1, and MUP mRNA were reverse transcribed before 
ampliﬁ  cation by PCR in the presence of 
32P-radiolabeled dCTP. The PCR condi-
tions and analysis method have been previously described (Ishigaki et al., 
2001). PCR products were quantiﬁ  ed with an imaging system (Typhoon 
9200; GE Healthcare).
Luciferase activity for translation efﬁ  ciency assay
HeLa cells were transfected with 2 μg pFluc and 1 μg pRluc. 24 h after 
transfection, cells were incubated with 0.01% DMSO (vol/vol), 5 μM 
NMDI 1 for 20 h, or 100 μg/ml CHX for 4 h before being harvested. 
Luciferase activity was quantiﬁ  ed on 2 × 10
5 cell equivalent on a lumino-
meter (MicroLumat LB 96P; Berthold Technologies) using the Dual-Glo lucif-
erase assay kit (Promega) according to the manufacturer’s instructions. The 
luciferase activity was normalized according to the level of Fluc and Rluc 
mRNA level measured by RPA.
Luciferase activity for miRNA decay pathway integrity
Cells were grown in six-well plates and transfected with Lipofectamine Plus 
reagent using 50 ng RLperfect RNA reporter (Pillai et al., 2005), 200 ng 
pGl3 plasmid coding for Fluc, and 4 μg pTzU6 plasmid (Good et al., 
1997). 24 h after transfection, NMDI 1 was added to corresponding 
wells. 48 h after transfection, luciferase activity was measured with a Dual-
Glo luciferase assay kit according to the manufacturer‘s instructions.
Measure of FLAG-hUPF1 phosphorylation level by 2D gel analysis
10
6 293T cells were transfected with 1 μg pCI-neo-FLAG-hUpf1 (provided 
by L. Maquat; Sun et al., 1998) using Lipofectamine Plus reagent accord-
ing to the manufacturer’s instructions. After 12 h, serum was removed from 
the culture medium for 24 h before adding 5 μM NMDI 1 or 0.01% 
DMSO (vol/vol) as a control for 3 h at 37°C and 5% CO2. 10% serum 
was added back for 1 h at 37°C and 5% CO2. Total proteins were puriﬁ  ed 
in a lysis buffer containing 8 M urea, 2% CHAPS, and 40 mM Tris base. 
The ﬁ  rst dimension was performed according to the protocol guide from 
GE Healthcare for 2D electrophoresis with immobilized pH gradient. 18-cm 
Immobiline DryStrip, pH 3–10 (GE Healthcare), was used to separate pro-
teins according to their isoelectric point. The second dimension was done 
by loading the ﬁ  rst dimension on a 10% SDS-PAGE. Finally, proteins were 
transferred to a nitrocellulose membrane before incubation with 1 μg of 
mouse anti–α-FLAG antibody (Sigma-Aldrich) in TBS containing 0.05% 
Tween overnight at 4°C followed by incubation with a peroxidase-conjugated 
goat anti–mouse antibody (Pierce Chemical Co.). Proteins were then 
detected using SuperSignal West Femto maximum sensitivity substrate 
(Pierce Chemical Co.).
Tethering assay
This experiment was performed as described previously (Hosoda et al., 2005).
Immunoﬂ  uorescence, FISH assays, and image analysis
HeLa cells were cultured on 12-mm glass coverslips in 10% DME (vol/vol) 
FBS. Cells (10
5) were transiently transfected with 500 ng of plasmids pGFP-
Ge1 (provided by D. Bloch, Harvard Medical School, Charleston, MA; 
Yu et al., 2005), pYFP-hSmg5, pYFP-hSmg6, pYFP-hSmg7 (all provided by 
E. Izaurralde, Max Planck Institute for Developmental Biology, Tuebingen, 
Germany; Unterholzner and Izaurralde, 2004), pGFP-hCcr4, pCFP-hDcp1a 
(both provided by B. Séraphin, Centre National de la Recherche Scienti-
ﬁ  que, Montpellier, France; Cougot et al., 2004), pCI-neo-FLAG-hUpf1 (Sun 
et al., 1998), pcDNA3-hUpf3-FLAG, pcDNA3-hUpf3X-FLAG (both provided 
by L. Maquat; Lykke-Andersen et al., 2000), pmCMV-Gl (Norm or 39Ter; 
Sun et al., 1998), pmCMV-GPx1 (Norm or 46Ter; Moriarty et al., 1998), 
pHA-hUpf1dNT, pHA-hSmg5dCT, or pHA-hSmg5DA (all three provided by 
S. Ohno and A. Yamashita, Yokohama City University School of Medicine, 
Yokohama, Japan; Ohnishi et al., 2003). 24 h after transfection, cells were 
treated with 5 μM NMDI 1 or 0.01% DMSO (vol/vol) as a control. 20 h 
later cells were ﬁ  xed using formalin solution (Sigma-Aldrich) for 10 min at 
room temperature and permeabilized in 70% ethanol overnight at 4°C. 
For immunoﬂ  uorescence assays, ﬁ  xed cells were incubated with a mouse 
anti-FLAG antibody (Sigma-Aldrich) for 2 h at room temperature, washed 
three times with PBS, and incubated with Cy3- or FITC-conjugated goat 
anti–mouse antibody (Jackson ImmunoResearch Laboratories) for 1 h at 
room temperature. Finally, cells were washed three times with PBS and 
incubated with 2 ng/μl of Hoechst stain (Sigma-Aldrich) for 2 min at room 
temperature. For FISH experiments, ﬁ   xed cells were incubated in a pre-
hybridization buffer (125 μg/ml tRNA, 500 μg/ml herring DNA, 1 mg/ml 
BSA, 0.1 g/ml dextran sulfate, 50% formamide, and 2× sodium saline 
citrate [SSC] buffer) at 37°C for 1 h in a tissue culture incubator. Fixed cells 
were incubated overnight in a tissue culture incubator with a hybridiza-
tion buffer (prehybridization buffer with Cy3-labeled probes), washed three 
times in 2× SSC at 37°C and three times in 1× SSC at room temperature, 
and incubated with 2 ng/μl of Hoechst stain (Sigma-Aldrich) for 2 min at 
room temperature. A Cy3 5′ and 3′ end–labeled probe (5′-C  G  A  T  C  T  G  C  G-
T  T  C  T  A  C  G  G  T  G  G  T  -3′) was used to detect Gl or GPx1 mRNA Ter. For Figs. 
5 B and 6 B, the MS2 probe sequence was 5′-AT*G  T  C  G  A  C  C  T  G  C  A  G  A  C  A  T  *-
G  G  G  T  G  A  T  C  C  T  C  A  T  *G  T  T  T  T  C  T  A  G  G  C  A  A  T  T  *A-3′ (the asterisks indicate an 
internal Cy3 modiﬁ  cation).
Fixed cells were observed in V  E  C  T  A  S  H  I  E  L  D   mounting medium 
(Vector Laboratories) with a microscope (DMRA; Leica) with an oil objective 
(PL APO 63×, NA 1.32; Leica) and A4 (for Hoechst stain), GFP, and Y3 (for 
Cy3) ﬁ  lter sets (Leica). Images were captured at 0.3-μm intervals along the 
z axis using a piezzo stepper (E662 LVPTZ ampliﬁ  er; Servo Products) and 
a cooled charge-coupled device camera (MicroMAX, 1,300 × 1,030 pix-
els, RS; Princeton Instruments Inc.) driven by MetaMorph v6.2 (Universal 
Imaging Corp.). Pixel sizes were 106 × 106 nm and voxel sizes were 106 × 
106 × 100 nm. For deconvolution and image reconstruction, xyz image 
stacks of ﬁ  xed cells were processed using deconvolution software (Huy-
gens 2.3; Scientiﬁ  c Volume Imaging) using a maximum likelihood estima-
tion algorithm. 3D restored stacks were processed with software (Imaris 4; 
Bitplane) for volume rendering and quantiﬁ  cation.
Down-regulation of hUPF2 or hXRN1
10
5 HeLa cells were transfected with 100 nM siRNA hUpf2 (Eurogentec; 
Kim et al., 2005) using a JetPEI reagent (PolyPlus Transfection) for 48 h be-
fore being harvested. The down-regulation efﬁ  ciency was then analyzed 
by Western blot or by immunoﬂ  uorescence.
Down-regulation of hXRN1 (provided by J. Lykke-Andersen, Univer-
sity of Colorado, Boulder, CO) has been previously described (Cougot 
et al., 2004).
Immunopuriﬁ  cation and Western blot analysis
hUPF1 immunopuriﬁ  cation and Western blot analysis were performed 
  according to the protocol described in Lejeune and Maquat (2004) using 
rabbit anti–α-hUPF1 antibody (provided by S. Ohno and A. Yamashita; 
Ohnishi et al., 2003). Western blot analyses were performed using 1:250 
rabbit anti–α-hUPF1, α-hSMG5, α-hSMG6, or α-hSMG7 antibodies (pro-
vided by S. Ohno and A. Yamashita; Ohnishi et al., 2003); 1:1,000 rab-
bit α-hUPF3/3X (Ishigaki et al., 2001); or 1:1,000 mouse anti–α-tubulin 
(Sigma-Aldrich). For Fig. 2, Western blot analysis was done with 1:1,000 
rabbit anti–α-hUPF1, 1:1,000 rabbit anti–α-hUPF2, and 1:1,000 rabbit 
anti–α-hUPF3/3X (Ishigaki et al., 2001). Proteins were detected using 
SuperSignal West Pico chemiluminescent substrate or SuperSignal West 
Femto maximum sensitivity substrate (Pierce Chemical Co.).
Online supplemental material
Fig. S1 shows that pre-mRNA splicing and mRNA translation are not af-
fected by NMDI 1. Fig. S2 conﬁ  rms the results of Fig. 2 by RPA approach 
and presents the evidence of the accumulation of FLAG-hUPF1 in P-bodies 
of 293T cells in the presence of NMDI 1 and serum. Fig. S3 shows that 
endogenous phosphorylated hUpf1, hSmg6, and hSmg7 are detected in 
P-bodies in the presence of NMDI 1. Fig. S4 demonstrates that GPx1-
Ter mRNA is present in P-bodies when NMD is blocked by NMDI 1. Finally, 
Table S1 shows the structures of compounds that have been used in this 
study. Online supplemental material is available at http://www.jcb.org/
content/full/jcb.200611086/DC1.
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